This article is more than 5 years old. Information may no longer be current.
Lumenis, Aravind to partner on glaucoma study in India
Click Here to Manage Email Alerts
SANTA CLARA, Calif. — The Aravind Eye Care System and Lumenis have announced plans to work together on a large analysis of the efficacy of selective laser trabeculoplasty compared with topical medical therapy as initial treatment for open-angle glaucoma in India, according to a press release from Lumenis.
The prospective, randomized, controlled clinical trial will compare Lumenis SLT to topical medication in terms of lowering IOP, side effects and cost. It also will contrast the two treatments on other clinical measures for glaucoma such as optic disc, visual field and visual acuity, according to the release.
The trial will include more than 600 patients recruited from four Aravind hospitals in India, "making it a robust study that is based on a purely homogenous population of Indian people," Pazit Pianka, MD, senior ophthalmologist and Lumenis Vision medical director, said.
SLT will be offered to study participants with early open-angle glaucoma, who will return for follow-up examinations 1 week after treatment and at 1, 3, 6, 9, 12, 18 and 24 months.
SLT is viewed as a potentially beneficial glaucoma treatment in India because many patients do not regularly take prescribed eye drops, according to the release.